title: Immunological hallmarks of JC virus replication in multiple sclerosis patients on long-term natalizumab therapy.
abstract: Progressive multifocal leukoencephalopathy (PML) is the main adverse effect of natalizumab. Detectable JC virus-specific effector memory T-cell (TEM) responses may indicate ongoing JCV replication. We detected JCV-specific TEM responses in blood of patients with multiple sclerosis (MS) treated with natalizumab, including 2 patients with PML. The frequency of detection of these responses increased with the time on natalizumab. Thus, a subset of MS patients exhibit immunological hallmarks of JCV replication during prolonged natalizumab therapy.
authors.affiliation: Service d'Immunologie Biologique, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France.
authors.forename: Houria
authors.initials: H
authors.lastname: Hendel-Chavez
authors.forename: Marie-Ghislaine
authors.initials: MG
authors.lastname: de Goër de Herve
authors.forename: Claire
authors.initials: C
authors.lastname: Giannesini
authors.forename: Anne-Aurélie
authors.initials: AA
authors.lastname: Mazet
authors.forename: Caroline
authors.initials: C
authors.lastname: Papeix
authors.forename: Céline
authors.initials: C
authors.lastname: Louapre
authors.forename: Audrey
authors.initials: A
authors.lastname: Chardain
authors.forename: Nassima
authors.initials: N
authors.lastname: Boutarfa
authors.forename: Marie
authors.initials: M
authors.lastname: Théaudin
authors.forename: David
authors.initials: D
authors.lastname: Adams
authors.forename: Jacques
authors.initials: J
authors.lastname: Gasnault
authors.forename: Bruno
authors.initials: B
authors.lastname: Stankoff
authors.forename: Yassine
authors.initials: Y
authors.lastname: Taoufik
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D001688:Biological Products / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects*; D007577:JC Virus / Q000276:immunology* / Q000502:physiology; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D000069442:Natalizumab; D013601:T-Lymphocytes / Q000276:immunology; D014779:Virus Replication
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D007155:Immunologic Factors; D000069442:Natalizumab